Canine Dilated Cardiomyopathy Doberman

This is a classic and concerning presentation for occult (Stage B2) Doberman Cardiomyopathy. The high arrhythmial burden places this dog at significant risk for sudden cardiac death, and the echo changes confirm progression that warrants immediate intervention.

Here is my recommended management plan:

1. Inotropic Support (Start Immediately):
Based on the PROTECT study, starting pimobendan at this stage is the standard of care. It has been shown to significantly delay the onset of congestive heart failure and prolong survival in Dobermans with occult DCM.
* Action: Start pimobendan 0.25–0.3 mg/kg PO q12h. Administer on an empty stomach for best absorption.

2. Antiarrhythmic Therapy (Start Immediately):
With 8,000 VPCs and complex ectopy, antiarrhythmic therapy is crucial to reduce the risk of sudden death. The choice between sotalol and mexiletine is a common clinical question.

* My Recommendation: I would initiate therapy with sotalol. Its combined Class II (beta-blocker) and Class III properties are often effective. The beta-blockade may also offer some cardioprotective benefits, though we must be mindful of its negative inotropic effects given the FS of 22%.
* Dose: Start at a conservative dose of 1.5–2 mg/kg PO q12h.
* Alternative/Adjunct: If a follow-up Holter shows inadequate control (>80% reduction in VPCs is a common goal) or if sotalol is not tolerated, the next step is typically to add mexiletine (5–8 mg/kg PO q8h) to the sotalol. Combination therapy is frequently required in severe cases like this. I generally do not use mexiletine as a sole agent initially unless beta-blockade is contraindicated.

3. Monitoring Protocol:
Close monitoring is essential to track progression and drug efficacy.
* Baseline: Before starting sotalol, obtain a baseline ECG and check renal values/electrolytes.
* 2–4 Weeks Post-Start: Recheck with a 24-hour Holter to assess the response to sotalol. Our goal is a significant reduction in VPCs and elimination of complex runs. Also, recheck renal values.
* Long-Term: Schedule rechecks every 6 months, including a full echocardiogram and 24-hour Holter.
* At Home: This is critical — instruct the owner on how to monitor and log the sleeping respiratory rate (SRR) daily. A sustained SRR >30 breaths/minute is the earliest sign of impending Stage C (CHF).

4. Prognosis:
You need to be direct with the owner. The prognosis for Doberman DCM is guarded to poor long-term. Even with aggressive management, the disease is progressive. Our goals are twofold: delay the onset of CHF (pimobendan) and reduce the risk of sudden death (sotalol/mexiletine). The median survival time from diagnosis of occult DCM is approximately 2-3 years, but the high arrhythmic burden in this case may place him in a higher-risk category.

In summary, I would start pimobendan and sotalol immediately. Counsel the owner on the importance of daily SRR monitoring and the guarded prognosis, and schedule a 2-4 week recheck Holter to assess antiarrhythmic efficacy. Let me know if the follow-up Holter is still concerning.